24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      G-CSF increases calprotectin expression, liver damage and neuroinflammation in a murine model of alcohol-induced ACLF

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and aims: Granulocyte colony-stimulating factor (G-CSF) has been proposed as a therapeutic option for patients with ACLF, however clinical outcomes are controversial. We aimed at dissecting the role of G-CSF in an alcohol-induced murine model of ACLF.

          Methods: ACLF was triggered by a single alcohol binge (5 g/kg) in a bile duct ligation (BDL) liver fibrosis model. A subgroup of mice received two G-CSF (200 μg/kg) or vehicle injections prior to acute decompensation with alcohol. Liver, blood and brain tissues were assessed.

          Results: Alcohol binge administered to BDL-fibrotic mice resulted in features of ACLF indicated by a significant increase in liver damage and systemic inflammation compared to BDL alone. G-CSF treatment in ACLF mice induced an increase in liver regeneration and neutrophil infiltration in the liver compared to vehicle-treated ACLF mice. Moreover, liver-infiltrating neutrophils in G-CSF-treated mice exhibited an activated phenotype indicated by increased expression of CXC motif chemokine receptor 2, leukotriene B4 receptor 1, and calprotectin. In the liver, G-CSF triggered increased oxidative stress, type I interferon response, extracellular matrix remodeling and inflammasome activation. Circulating IL-1β was also increased after G-CSF treatment. In the cerebellum, G-CSF increased neutrophil infiltration and S100a8/9 expression, induced microglia proliferation and reactive astrocytes, which was accompanied by oxidative stress, and inflammasome activation compared to vehicle-treated ACLF mice.

          Conclusion: In our novel ACLF model triggered by alcohol binge that mimics ACLF pathophysiology, neutrophil infiltration and S100a8/9 expression in the liver and brain indicate increased tissue damage, accompanied by oxidative stress and inflammasome activation after G-CSF treatment.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Mouse model of chronic and binge ethanol feeding (the NIAAA model).

          Chronic alcohol consumption is a leading cause of chronic liver disease worldwide, leading to cirrhosis and hepatocellular carcinoma. Currently, the most widely used model for alcoholic liver injury is ad libitum feeding with the Lieber-DeCarli liquid diet containing ethanol for 4-6 weeks; however, this model, without the addition of a secondary insult, only induces mild steatosis, slight elevation of serum alanine transaminase (ALT) and little or no inflammation. Here we describe a simple mouse model of alcoholic liver injury by chronic ethanol feeding (10-d ad libitum oral feeding with the Lieber-DeCarli ethanol liquid diet) plus a single binge ethanol feeding. This protocol for chronic-plus-single-binge ethanol feeding synergistically induces liver injury, inflammation and fatty liver, which mimics acute-on-chronic alcoholic liver injury in patients. This feeding protocol can also be extended to chronic feeding for longer periods of time up to 8 weeks plus single or multiple binges. Chronic-binge ethanol feeding leads to high blood alcohol levels; thus, this simple model will be very useful for the study of alcoholic liver disease (ALD) and of other organs damaged by alcohol consumption.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Acute-on-Chronic Liver Failure

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              S100A8/A9: From basic science to clinical application.

              Neutrophils and monocytes belong to the first line of immune defence cells and are recruited to sites of inflammation during infection or sterile injury. Both cells contain huge amounts of the heterodimeric protein S100A8/A9 in their cytoplasm. S100A8/A9 belongs to the Ca(2+) binding S100 protein family and has recently gained a lot of interest as a critical alarmin modulating the inflammatory response after its release (extracellular S100A8/A9) from neutrophils and monocytes. Extracellular S100A8/A9 interacts with the pattern recognition receptors Toll-like receptor 4 (TLR4) and Receptor for Advanced Glycation Endproducts (RAGE) promoting cell activation and recruitment. Besides its biological function, S100A8/A9 (also known as myeloid related protein 8/14, MRP8/14) was identified as interesting biomarker to monitor disease activity in chronic inflammatory disorders including inflammatory bowel disease and rheumatoid arthritis. Furthermore, S100A8/A9 has been tested successfully in pre-clinical imaging studies to localize sites of infection or sterile injury. Finally, recent evidence using small molecule inhibitors for S100A8/A9 also suggests that blocking S100A8/A9 activity exerts beneficial effects on disease activity in animal models of autoimmune diseases including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease. This review will provide a comprehensive and detailed overview into the structure and biological function of S100A8/A9 and also will give an outlook in terms of diagnostic and therapeutic applications targeting S100A8/A9.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/2580604/overviewRole: Role:
                URI : https://loop.frontiersin.org/people/2624208/overviewRole: Role: Role:
                URI : https://loop.frontiersin.org/people/2646064/overviewRole: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/1195153/overviewRole: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/1715383/overviewRole: Role:
                URI : https://loop.frontiersin.org/people/1500551/overviewRole: Role:
                Role: Role:
                URI : https://loop.frontiersin.org/people/1496901/overviewRole: Role: Role: Role: Role: Role:
                Journal
                Front Cell Dev Biol
                Front Cell Dev Biol
                Front. Cell Dev. Biol.
                Frontiers in Cell and Developmental Biology
                Frontiers Media S.A.
                2296-634X
                14 February 2024
                2024
                : 12
                : 1347395
                Affiliations
                [1] 1 Department of Medicine , Division of Gastroenterology , Beth Israel Deaconess Medical Center and Harvard Medical School , Boston, MA, United States
                [2] 2 Broad Institute , Cambridge, MA, United States
                Author notes

                Edited by: Matheus Mattos, KU Leuven, Belgium

                Reviewed by: Yun Liao, Cornell University, United States

                Kyle Poulsen, University of Texas Health Science Center at Houston, United States

                *Correspondence: Gyongyi Szabo, gszabo1@ 123456bidmc.harvard.edu
                Article
                1347395
                10.3389/fcell.2024.1347395
                10899467
                38419842
                592ce5f5-c91c-4586-a960-c3c7f5bd3555
                Copyright © 2024 Ortega-Ribera, Zhuang, Brezani, Thevkar Nagesh, Joshi, Babuta, Wang and Szabo.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 30 November 2023
                : 23 January 2024
                Funding
                Funded by: National Institutes of Health , doi 10.13039/100000002;
                Award ID: R01 AA017729 R01 AA020744 R01 AA011576
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by NIH grants R01 AA017729, R01 AA020744, and R01 AA011576 (to GS).
                Categories
                Cell and Developmental Biology
                Original Research
                Custom metadata
                Molecular and Cellular Pathology

                acute-on-chronic liver failure,inflammasome,s100a8/s100a9,neutrophil,bdl,cerebellum,encephalopathy,ethanol

                Comments

                Comment on this article